Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) is reporting third quarter financial results on Monday 2nd November 2020, before market open.
According to analysts surveyed by Thomson Reuters, HZNP is expected to report 3Q20 income of $ 0.97 per share from revenue of $ 525.08 million.
For the full year, analysts anticipate top line of $ 1945.43 million, while looking forward to income of $ 2.91 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,850.00 million ~ $ 1,900.00 million
Click Here For More Historical Outlooks Of Horizon Therapeutics Public Limited Company
Previous Quarter Performance
Horizon Therapeutics Public Limited Company outlined income for the second quarter of $ 0.40 per share, from the revenue of $ 462.78 million. The quarterly earnings down 18.37 percent while revenues escalated 44.33 percent compared with the same quarter last year.
According to street consensus, HZNP was expected to report 2Q20 income of $ 0.36 per share from revenue of $ 332.45 million. The bottom line results beat street analysts by $ 0.04 or 11.11 percent, at the same time, top line results outshined analysts by $ 130.33 million or 39.20 percent.
Stock Performance
On Friday, shares of Horizon Therapeutics Public Limited Company has traded high as $ 77.91 and has cracked $ 73.75 on the downward trend, reaching $ 74.93 with volume of 2.85 million shares.
According to the previous trading day, closing price of $ 74.93, representing a 226.42 % increase from the 52 week low of $ 23.81 and a 10.33 % decrease over the 52 week high of $ 86.67.
The company has a market capital of $ 16.51 billion and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Recent Analyst recommendations
- On 9th September 2020, initiated by JPMorgan Chase & Co. at Overweight rating, with $ 110.00 target price.
Conference Call
Horizon Therapeutics Public Limited Company will be hosting a conference call at 8:00 AM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.horizontherapeutics.com
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The companys primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants.
